Harnessing the power of immunotherapy and targeted therapy: translating evidence into practice

Invitation

Tuesday 6 December 2016
17.45–19.15

Hall C2
Messe Wien Exhibition & Congress Center
Vienna, Austria
Harnessing the power of immunotherapy and targeted therapy: translating evidence into practice

As we will witness again here in Vienna, the treatment of non-small cell lung cancer (NSCLC) has entered another exciting period of intense development. The advances made in recent years have been astounding, and rapidly translating the benefits observed in medical research to daily clinical practice has become an important challenge for the whole oncology community. In this symposium, highly respected experts in NSCLC care will discuss the latest data on targeted therapy and immunotherapy, and consider how these lessons can be applied to benefit individual patients. We hope that you will be able to attend and actively participate in this engaging session, and look forward to welcoming you there.

Programme

17.45  Introduction  
Dr David Spigel (USA) [Chair]

17.50  ALK: the power of targeted therapy  
Prof Frank Griesinger (Germany)

18.15  Latest developments in the treatment of EGFR Mut+ NSCLC  
Dr Federico Cappuzzo (Italy)

18.30  The power of the immune system: immunotherapy in practice  
Dr Achim Rittmeyer (Germany)

19.10  Summary and Close  
Dr David Spigel